GlassScriptPhysician profile
Zack Lazar
NPI 1942750328
$2,557.07
in general payments reported to CMS, 2019-2025
18 companies · $22.19 in 2025
The $22.19 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $827 · 2023: $1,141 · 2024: $400 · 2025: $22.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.33 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $316.77 | 2022-2023 | Rexulti |
| Corium, LLC | $273.36 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $247.56 | 2022-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $233.14 | 2023-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $195.72 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $120.97 | 2022-2023 | Austedo, Austedo Xr |
| Lundbeck LLC | $119.08 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $110.70 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.74 | 2023 | |
| Neurocrine Biosciences, INC. | $69.85 | 2022 | |
| Bausch Health US, LLC | $62.93 | 2022-2023 | Aplenzin |
| Axsome Therapeutics, INC. | $55.87 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $33.74 | 2021-2024 | Adzenys Xr-Odt |
| Biogen, INC. | $25.80 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $22.31 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $16.73 | 2023 | Quviviq |
| Indivior INC. | $16.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zack Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.